Has Jacqueline Kelly, MD received payments from drug or device companies?

Yes. Drug and device makers reported $4,849 in general payments to Jacqueline Kelly, MD across 262 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Jacqueline Kelly, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Jacqueline Kelly, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Jacqueline Kelly, MD

Radiation Oncology · Lincoln, NENPI 1730507971

Payments from drug & device makers

$4,849in general payments, 2019–2025

Across 262 payments — averaging $18.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Johnson & Johnson$293
AstraZeneca$284
Visionrt, Inc.$265
Merck$255
Novartis$251
Eisai Inc.$199
plus $3K from 54 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Johnson & Johnson(2 entities)	17	$293
AstraZeneca	14	$284
Visionrt, Inc.	3	$265
Merck	13	$255
Novartis	15	$251
Eisai Inc.	10	$199
Daiichi Sankyo Inc.	11	$197
Pfizer	11	$188
Amgen	9	$168
Lilly USA, LLC	10	$161
Astellas Pharma US Inc	8	$149
Genentech USA, Inc.	8	$144
Servier Pharmaceuticals LLC	7	$137
Regeneron Healthcare Solutions, Inc.	6	$134
Seagen Inc.	8	$123
Takeda Pharmaceuticals U.S.A., Inc.	8	$121
AbbVie	6	$120
Gilead(2 entities)	6	$113
Bayer	6	$105
Ipsen Biopharmaceuticals, Inc	5	$92
Incyte Corporation	6	$89
Tersera Therapeutics LLC	3	$80
Taiho Oncology, Inc.	5	$79
Foundation Medicine, Inc.	3	$60
Puma Biotechnology, Inc.	4	$54
Blueprint Medicines Corporation	3	$51
Boston Scientific	3	$51
Iovance Biotherapeutics, Inc.	2	$50
Adaptive Biotechnologies Corporation	3	$47
Genmab U.S., Inc.	2	$47
E.r. Squibb & Sons, L.L.C.	3	$45
Sanofi	3	$44
CSL Behring	2	$42
Tolmar, Inc.	2	$36
GSK	2	$35
Karyopharm Therapeutics Inc.	2	$35
EMD Serono, Inc.	2	$34
Pharmacosmos Therapeutics Inc.	2	$32
Tolmar Pharmaceuticals, Inc.	2	$31
Pharmaessentia USA Corporation	2	$29
G1 Therapeutics, Inc.	2	$28
AMAG Pharmaceuticals, Inc.	2	$27
Mirati Therapeutics, Inc.	1	$26
Novo Nordisk	1	$19
Sobi, Inc	1	$18
AVEO Pharmaceuticals, Inc.	1	$18
Azurity Pharmaceuticals, Inc.	1	$17
Novocure Inc.	1	$17
Kyowa Kirin, Inc.	1	$16
Boehringer Ingelheim	1	$16
Fresenius Kabi USA, LLC	1	$15
Clovis Oncology, Inc.	1	$15
Genentech, Inc.	1	$15
Exelixis Inc.	1	$15
Stemline Therapeutics Inc.	1	$15
Spectrum Pharmaceuticals Inc.	1	$14
Jazz Pharmaceuticals Inc.	1	$14
Sun Pharmaceutical Industries Inc.	1	$14
Morphosys, US Inc.	1	$14
Myovant Sciences Inc.	1	$13

How this compares

$4,849 in reported general payments places this provider in the 90th percentile of 32 radiation oncology providers in Nebraska.

See all radiation oncology providers in Nebraska →

Medicare billing

Part B allowed, 2024

$784,330

Medicare patients

404

Services billed

5,278

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other radiation oncology in Lincoln

Joseph Kam ChiuLincoln$12K
Mark StavasLincoln$4K
Phillip HynesLincoln$2K
Kevin YieeLincoln$1K
Raju RaoLincoln$109
Bennett BarriosLincoln$23
Hadi ZahraNorfolk$15K
Alireza MirmiranOmaha$13K
Michael BaineOmaha$4K
Tien Shew HuangOmaha$2K

See the full list for Nebraska →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →